Vilaseca I, Sampieri C, Lehrer E, Ramirez R, Costa J, Valduvieco I
Eur Arch Otorhinolaryngol. 2025; .
PMID: 40087170
DOI: 10.1007/s00405-025-09315-x.
Chen G, Kong X, Feng Z, Kang J, Han Z, Li B
BMC Oral Health. 2025; 25(1):383.
PMID: 40082913
PMC: 11907896.
DOI: 10.1186/s12903-025-05694-z.
Kim C, Han M, Kim G, Son W, Kim J, Gil M
Cancer Immunol Immunother. 2025; 74(4):144.
PMID: 40063100
PMC: 11893940.
DOI: 10.1007/s00262-025-03959-8.
Ren Y, Xiong W, Feng C, Yu D, Wang X, Yang Q
Commun Biol. 2025; 8(1):370.
PMID: 40044946
PMC: 11882983.
DOI: 10.1038/s42003-025-07700-0.
Cui J, Wang J, Yue A, Cao J, Zhang Z, Shi B
Sci Rep. 2025; 15(1):6871.
PMID: 40011690
PMC: 11865501.
DOI: 10.1038/s41598-025-91129-2.
MRI in Oral Tongue Squamous Cell Carcinoma: A Radiomic Approach in the Local Recurrence Evaluation.
Vidiri A, Dolcetti V, Mazzola F, Lucchese S, Laganaro F, Piludu F
Curr Oncol. 2025; 32(2).
PMID: 39996916
PMC: 11854587.
DOI: 10.3390/curroncol32020116.
FTO-mediated mA demethylation of SERPINE1 mRNA promotes tumor progression in hypopharyngeal squamous cell carcinoma.
Sa N, Liu X, Hao D, Lv Z, Zhou S, Yang L
Transl Cancer Res. 2025; 14(1):595-612.
PMID: 39974406
PMC: 11833370.
DOI: 10.21037/tcr-2024-2507.
Survival analysis of laryngeal squamous cell cancer, considering different treatment modalities and other factors influencing survival - a monocentric retrospective investigation.
Repassy G, Molnar A, Maihoub S, Hargas D, Tamas L
Eur Arch Otorhinolaryngol. 2025; .
PMID: 39961835
DOI: 10.1007/s00405-025-09229-8.
Predicting progression-free survival using dynamic contrast-enhanced imaging-based radiomics in advanced nasopharyngeal carcinoma patients treated with nimotuzumab.
Jin X, Li W, Guo Y, Wu G, Huang W, Chen F
Eur Radiol. 2025; .
PMID: 39953153
DOI: 10.1007/s00330-025-11433-3.
Efficacy of adjuvant external beam radiotherapy and brachytherapy in squamous cell carcinoma of oral tongue: Long-term outcomes.
Shojaei S, Mousavi A, Rahimzadeh P, Kazemian A, Aghili M, Ghalehtaki R
J Contemp Brachytherapy. 2025; 16(6):398-409.
PMID: 39943970
PMC: 11812135.
DOI: 10.5114/jcb.2024.146837.
Nomogram Prediction of Response to Neoadjuvant Chemotherapy Plus Pembrolizumab in Locally Advanced Hypopharyngeal Squamous Cell Carcinoma.
Hu Z, Chen Y, Ma R, Sun W, Chen L, Cai Z
J Otolaryngol Head Neck Surg. 2025; 54:19160216251318255.
PMID: 39921555
PMC: 11807280.
DOI: 10.1177/19160216251318255.
Evaluating the influence of anti-PD-1 immunotherapy combined with IMRT on thyroid dysfunction in nasopharyngeal carcinoma.
Chen L, Li Z, Li X, Wu S, Gong L, Xu G
Front Immunol. 2025; 15:1495946.
PMID: 39885990
PMC: 11779716.
DOI: 10.3389/fimmu.2024.1495946.
Salivary biomarkers for early detection of oral squamous cell carcinoma (OSCC) and head/neck squamous cell carcinoma (HNSCC).
Li C, Deng S
Jpn Dent Sci Rev. 2025; 61:3-4.
PMID: 39885952
PMC: 11779649.
DOI: 10.1016/j.jdsr.2024.12.002.
The relevance of dental management prior to radiation therapy with severe oral mucositis in head and neck cancer patients.
Wang Y, Huang Z, Xiao S, Zheng B, Zhao D, Liu W
J Dent Sci. 2025; 20(1):522-528.
PMID: 39873060
PMC: 11762214.
DOI: 10.1016/j.jds.2024.04.030.
Evaluating H2BC9 as a potential diagnostic and prognostic biomarker in head and neck squamous cell carcinoma.
Wu L, Li L, Zhu M, Zhou Z, Su X, Jiang Y
Eur J Med Res. 2025; 30(1):54.
PMID: 39865289
PMC: 11771076.
DOI: 10.1186/s40001-025-02301-3.
A Narrative Review of Prognostic Gene Signatures in Oral Squamous Cell Carcinoma Using LASSO Cox Regression.
Mohd Faizal N, Shai S, Savaliya B, Karen-Ng L, Kumari R, Kumar R
Biomedicines. 2025; 13(1).
PMID: 39857718
PMC: 11759772.
DOI: 10.3390/biomedicines13010134.
Heterogeneity analysis and prognostic model construction of HPV negative oral squamous cell carcinoma T cells using ScRNA-seq and bulk-RNA analysis.
Li C, Lv Z, Li C, Yang S, Liu F, Zhang T
Funct Integr Genomics. 2025; 25(1):25.
PMID: 39849233
PMC: 11759468.
DOI: 10.1007/s10142-024-01525-6.
Individualized treatment recommendations for patients with locally advanced head and neck squamous cell carcinoma utilizing deep learning.
Zhang L, Zhu E, Shi J, Wu X, Cao S, Huang S
Front Med (Lausanne). 2025; 11():1478842.
PMID: 39835092
PMC: 11744519.
DOI: 10.3389/fmed.2024.1478842.
Microinvasive oral squamous cell carcinoma: A management protocol.
Pal U, Devi S, Sowmya M, Maurya H, Kumar S, Singh R
Natl J Maxillofac Surg. 2025; 15(3):349-352.
PMID: 39830452
PMC: 11737556.
DOI: 10.4103/njms.njms_81_23.
Anticancer effect of the antirheumatic drug leflunomide on oral squamous cell carcinoma by the inhibition of tumor angiogenesis.
Niwata C, Nakagawa T, Naruse T, Sakuma M, Yamakado N, Akagi M
Discov Oncol. 2025; 16(1):53.
PMID: 39815040
PMC: 11735718.
DOI: 10.1007/s12672-025-01763-5.